![William Scott](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
William Scott
Corporate Officer/Principal bei
The Rockefeller University
Profil
Dr. William A. Scott has extensive research and management experience in both biotechnology and large pharmaceutical companies.
Bill was previously Chief Executive Officer of Physiome Sciences, Inc., a company whose mission is to help pharmaceutical companies develop better drugs faster through the use of biological simulations.
Prior to that, he held various senior level positions at Bristol-Myers Squibb (“BMS”) including Senior Vice President, Exploratory and Drug Discovery Research at BMS Pharmaceutical Research Institute from 1990 through 1996.
During this period, he oversaw the submission of over 70 new chemical entities for development as new therapeutic agents.
He consults or serves as a member of the board of directors of several biotechnology companies, including serving on the boards of publicly-traded AtheroGenics, Inc., Deltagen, Inc. and Variagenics, Inc. Bill holds a B.S.
in Chemistry from University of Illinois and a Ph.D.
in Biochemistry from the California Institute of Technology.
He is also an Adjunct Professor at the Rockefeller University, where he has been affiliated since 1969.
Aktive Positionen von William Scott
| Unternehmen | Position | Beginn |
|---|---|---|
The Rockefeller University
 The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.1969 |
KBL Healthcare Ventures
 KBL Healthcare Ventures Investment ManagersFinance KBL Healthcare invests in companies located in the United States. The firm targets companies operating in the fields of life sciences, medical devices, healthcare services and medical information technology. It provides financing for early stage capital requirements. | Berater | - |
Ehemalige bekannte Positionen von William Scott
| Unternehmen | Position | Ende |
|---|---|---|
AtheroGenics, Inc.
 AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs for the treatment of chronic inflammatory diseases | Direktor/Vorstandsmitglied | 14.07.2009 |
Variagenics, Inc.
 Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops technologies related to pharmaco-genomics | Direktor/Vorstandsmitglied | 15.11.2006 |
Physiome Sciences, Inc.
 Physiome Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Provides computer-based modeling and simulation of cells, and biological systems for drug development | Präsident | 01.01.1999 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 31.12.1996 |
CombiChem, Inc.
 CombiChem, Inc. Miscellaneous Commercial ServicesCommercial Services Provides drug recovery services | Direktor/Vorstandsmitglied | - |
Ausbildung von William Scott
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
78
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
CombiChem, Inc.
CombiChem, Inc. Miscellaneous Commercial ServicesCommercial Services Provides drug recovery services | Commercial Services |
AtheroGenics, Inc.
AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs for the treatment of chronic inflammatory diseases | Health Technology |
Deltagen, Inc.
 Deltagen, Inc. Miscellaneous Commercial ServicesCommercial Services Provides drug discovery tools and services to the biopharmaceutical industry | Commercial Services |
VenGrowth Capital Partners, Inc.
 VenGrowth Capital Partners, Inc. Investment ManagersFinance The VenGrowth Funds invest in small and mid-sized private Canadian companies in the technology, life sciences and tradition industries sectors. The Criterion Global Dividend Fund invests in blue-chip multinational companies selected by Merrill Lynch International. The Fund is also available unhedged. The Criterion International Equity Fund is actively sub-advised by The Boston Company. The Fund invests in international stocks outside of North America, with a GARP strategy. It is also available unhedged. The Criterion Water Infrastructure Fund invests globally in companies related to water delivery. The Fund is also available unhedged. The Criterion Global Clean Energy Fund invests in companies involved in the global transition to cleaner energies and lower carbon emissions. The Fund is also available unhedged. The Criterion Diversified Commodities Currency Hedged Fund allows Canadian investors to participate directly in the diversified commodities index UBS Bloomberg CMCI AM. The Criterion US Buyback Fund invests in US companies with the best record of net share buybacks. It is also available unhedged. | Finance |
Variagenics, Inc.
Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops technologies related to pharmaco-genomics | Commercial Services |
Physiome Sciences, Inc.
Physiome Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Provides computer-based modeling and simulation of cells, and biological systems for drug development | Commercial Services |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avalon Pharmaceuticals, Inc.
 Avalon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics products | Health Technology |
KBL Healthcare Ventures
KBL Healthcare Ventures Investment ManagersFinance KBL Healthcare invests in companies located in the United States. The firm targets companies operating in the fields of life sciences, medical devices, healthcare services and medical information technology. It provides financing for early stage capital requirements. | Finance |
Targanta Therapeutics, Inc.
 Targanta Therapeutics, Inc. BiotechnologyHealth Technology Develops antibiotic drugs and other related products | Health Technology |
The Rockefeller University
The Rockefeller University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wählen Sie MarketScreener 
